The US Food and Drug Administration has expanded the approval of Roche’s Tecentriq so that it can be used to treat a wider range of patients with bladder cancer.
MAKE IT MODERN
Three new specialised treatments are now to be made available on the NHS for patients in England after being initially rejected for funding back in December, NHS England has announced.
The FDA has largely succeeded in expediting the review of drugs with larger health gains, but postmarket trials by companies have fallen behind in confirming some of those benefits, with many not using the gold standard of randomized controlled trials, according to two independent studies.
Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
The prescription charge in England will rise next month by 20 pence to £8.60 for each medicine or appliance dispensed, the government has announced, once again bringing to the fore the debate over the fairness of charges throughout the UK.
The European Medicines Agency’s working group on good clinical practices and inspections outlined its goals for 2017, including plans to prioritize certain site inspections.
US regulators have agreed to undertake a priority review Merck and Pfizer's avelumab as a potential treatment for metastatic urothelial carcinoma (mUC).